EUVIMEDEUVIMED entdecken
Open Access

Nanoengineered mesenchymal stem cell therapy for pulmonary fibrosis in young and aged mice

Meng-Meng Han iD, Xing-Yue He iD, Ling Tang iD, Liang Qi iD, Ming-Yuan Yang, Yi Wang iD, Lei Xing iD, Jee-Heon Jeong iD, Hu-Lin Jiang iD

Science Advances · 21.07.2023 · 9 (29)

DOI: 10.1126/sciadv.adg5358 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Advances, erschienen am 21.07.2023. Verfasst von Meng-Meng Han und 8 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Natural Medicines, Department of Pharmaceutics, China Pharmaceutical University, Nanjing 210009, China. Hauptthemen laut MEDLINE: Pulmonary Fibrosis, Mesenchymal Stem Cell Transplantation, Mesenchymal Stem Cells. Die Arbeit wurde bisher 92-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pulmonary fibrosis (PF) is an age-related interstitial lung disease that results in notable morbidity and mortality. The Food and Drug Administration–approved drugs can decelerate the progression of PF; however, curing aged patients with severe fibrosis is ineffective because of insufficient accumulation of these drugs and wide necrocytosis of type II alveolar epithelial cells (AEC IIs). Here, we constructed a mesenchymal stem cell (MSC)–based nanoengineered platform via the bioconjugation of MSCs and type I collagenase–modified liposomes loaded with nintedanib (MSCs-Lip@NCAF) for treating severe fibrosis. Specifically, MSCs-Lip@NCAF migrated to fibrotic lungs because of the homing characteristic of MSCs and then Lip@NCAF was sensitively released. Subsequently, Lip@NCAF ablated collagen fibers, delivered nintedanib into fibroblasts, and inhibited fibroblast overactivation. MSCs differentiated into AEC IIs to repair alveolar structure and ultimately promote the regeneration of damaged lungs in aged mice. Our findings indicated that MSCs-Lip@NCAF could be used as a promising therapeutic candidate for PF therapy, especially in aged patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pulmonary FibrosisMesenchymal Stem Cell TransplantationMesenchymal Stem CellsUnited StatesAnimalsMiceLungAlveolar Epithelial Cells

Autor:innen und Institutionen

  • State Key Laboratory of Natural Medicines, Department of Pharmaceutics, China Pharmaceutical University, Nanjing 210009, China.
  • Department of Endocrinology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing 210009, China.
  • Jiangsu Key Laboratory of Druggability of Biopharmaceuticals, China Pharmaceutical University, Nanjing 210009, China.
  • Department of Precision Medicine, School of Medicine, Sungkyunkwan University, Suwon 16419, Republic of Korea.
  • College of Pharmacy, Yanbian University, Yanji 133002, China.

ORCID-Profile: Meng-Meng Han, Xing-Yue He, Ling Tang, Liang Qi, Yi Wang, Lei Xing, Jee-Heon Jeong, Hu-Lin Jiang

Zitieren

APA

Han, M. M., He, X. Y., Tang, L., Qi, L., Yang, M. Y., Wang, Y., Xing, L., Jeong, J. H., & Jiang, H. L. (2023). Nanoengineered mesenchymal stem cell therapy for pulmonary fibrosis in young and aged mice. Science Advances, 9(29). https://doi.org/10.1126/sciadv.adg5358

Vancouver

Han MM, He XY, Tang L, Qi L, Yang MY, Wang Y, et al. Nanoengineered mesenchymal stem cell therapy for pulmonary fibrosis in young and aged mice. Science Advances. 2023;9(29). doi:10.1126/sciadv.adg5358

BibTeX
@article{Han2023,
  author = {Han, Meng-Meng and He, Xing-Yue and Tang, Ling and Qi, Liang and Yang, Ming-Yuan and Wang, Yi and Xing, Lei and Jeong, Jee-Heon and Jiang, Hu-Lin},
  title = {Nanoengineered mesenchymal stem cell therapy for pulmonary fibrosis in young and aged mice},
  journal = {Science Advances},
  year = {2023},
  volume = {9},
  number = {29},
  doi = {10.1126/sciadv.adg5358}
}
Kostenlos starten →